.ELIXIR (European Life Science Infrastructure for Biological Information) is a pan-European organization founded in 2014 which aims to integrate and harmonize European bioinformatics infrastructures. ELIXIR coordinates the participation of more than 22 countries; engages with other strategic European initiatives and projects, e.G. ESFRI, Research Data Alliance, EUDat and EGI; promotes specific training activities and workshops on ELIXIR resources, partners with industry, and plays a key role in shaping the bioinformatics landscape. Spain has been a member of ELIXIR since 2015, with the Spanish National Bioinformatics Institute (INB) as the Spanish national node. Within ELIXIR, the INB is responsible for the bioinformatics infrastructure offered by Spain and, therefore, should guarantee its alignment with the strategic areas put forward by ELIXIR.Since 2018, the INB has two overarching objectives: deepen the alignment of its activities with ELIXIR, and increase the translational impact of INB actions towards the Spanish National Health System (SNS). For the latter objective, the INB has created and supports TransBioNet (Translational Bioinformatics Network), which aims to structure, bring together and work with bioinformatics groups in healthcare settings with a particular focus on the Health Research Institutes (IIS) recognized by the ISCIII. Since 2021, the INB has continued its activities in the context of IMPaCT-Data, the Data Science programme of IMPaCT. IMPaCT is the Spanish National Infrastructure for Personalized Medicine associated with Science and Technology by the National Health Research Institute Carlos III (ISCIII) .In 2022, the European Commission launched several flagship projects focused on using and re-using biomedical data to enable and accelerate research activities. In this context, the BSC participates in the European Genomic Infrastructure (GDI) and the EUropean federation for CAncer IMages (EUCAIM). The GDI project will enable access to genomic and related phenotypic and clinical data across Europe. It is doing that by establishing a federated, sustainable and secure infrastructure to access the available data. GDI builds on the outputs of the Beyond 1 Million Genomes (B1MG) project and is realizing the ambition of the 1+Million Genomes (1+MG) initiative and represents the implementation phase of the overall ambition of enabling the use of genomics data for precision medicine. Regarding EUCAIM, it is the cornerstone of the European Commission-initiated European Cancer Imaging Initiative, a flagship of Europe's Beating Cancer Plan (EBCP), which aims to foster innovation and deployment of digital technologies in cancer treatment and care to achieve more precise and faster clinical decision-making, diagnostics, treatment and predictive medicine for cancer patients. The ultimate goal is to deploy a pan-European digital federated infrastructure of FAIR cancer-related, de-identified, real-world images
